Delving into the Latest Updates on INNOLIFE CO., LTD. with Synapse

Overview

Tags

Cardiovascular Diseases

Nervous System Diseases

Digestive System Disorders

Chemical drugs

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	2
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Chemical drugs	4
Small molecule drug	1

Top 5 Target	Count

Cu x HIF-1α	1

目的：主要目的：评价12周时INL1（盐酸曲恩汀）与安慰剂相比在NYHA 心功能分级Ⅱ～Ⅲ级伴左心室射血分数降低（LVEF<40%）的心力衰竭患者中的疗效。次要目的：评价INL1（盐酸曲恩汀）与安慰剂相比在心力衰竭患者中的安全性和耐受性。描述12周治疗期间INL1（盐酸曲恩汀）的药代动力学（PK）特征

[Translation]

Objective: Primary objective: To evaluate the efficacy of INL1 (trientine hydrochloride) compared with placebo in patients with heart failure of NYHA class II-III with reduced left ventricular ejection fraction (LVEF<40%) at 12 weeks. Secondary objective: To evaluate the safety and tolerability of INL1 (trientine hydrochloride) compared with placebo in patients with heart failure. To describe the pharmacokinetic (PK) characteristics of INL1 (trientine hydrochloride) during 12 weeks of treatment

Start Date01 Jul 2021

Sponsor / Collaborator

Frontage Laboratories, Inc.

[+2]

NCT03875183

/ Unknown statusPhase 2

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction

This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in patients with chronic stable Heart Failure (HF) and reduced Left Ventricular Ejection Fraction (LVEF) to evaluate the efficacy and safety of three INL1 doses compared with placebo. Patients will be treated for approximately 12 weeks with one of three INL1 doses: 50 mg, 150 mg, 300 mg, or, placebo capsules, taken twice daily (BID).

Start Date20 Jan 2020

Sponsor / Collaborator

INNOLIFE CO., LTD.

100 Clinical Results associated with INNOLIFE CO., LTD.

Login to view more data

0 Patents (Medical) associated with INNOLIFE CO., LTD.

Login to view more data

100 Deals associated with INNOLIFE CO., LTD.

Login to view more data

100 Translational Medicine associated with INNOLIFE CO., LTD.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

1

Phase 2 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Trientine Hydrochloride ( Cu x HIF-1α )	Heart Failure More	Phase 2
INL-5	Liver Cirrhosis More	Preclinical
INL-4	Arteriosclerosis More	Preclinical
INL-3	Hypertension More	Preclinical
INL-2	Brain Infarction More	Preclinical